{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-027582","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.732771+00:00","generated_at":"2026-06-05T01:13:57.362038+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint reports Q4/FY2023 results; positive Phase 2 data for EYP-1901 in wet AMD","bullets":["Q4 net loss $14.1M ($0.33/sh) vs $43.5M ($1.16/sh) YoY; total net revenue $14.0M (+33%).","Cash and investments $331M as of Dec 31, 2023, funding operations through Phase 3 topline data for wet AMD in 2026.","Positive Phase 2 DAVIO 2 data: EYP-1901 met all primary/secondary endpoints; first Phase 3 trial expected 2H 2024.","First patient dosed in Phase 2 VERONA trial for DME; topline data 1Q 2025; PAVIA NPDR data expected 2Q 2024.","Appointed Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-027582","json":"https://secwatch.observer/filing/0000950170-24-027582.json","markdown":"https://secwatch.observer/filing/0000950170-24-027582.md","text":"https://secwatch.observer/filing/0000950170-24-027582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024027582/0000950170-24-027582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024027582/eypt-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:13:57.362038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06edc37a321e871e4b97a072dcced8ab00fe409d","claim":"EyePoint, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 7, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023 and certain other information.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024027582/0000950170-24-027582-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}